Opinion|Videos|January 29, 2025
BCG-Unresponsive NMIBC and Treatments
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options include cystectomy, intravesical chemotherapy, immunotherapy, or clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When do you consider a patient to have BCG-unresponsive disease?
- What treatment options are available for BCG-unresponsiveness/intolerance in patients?
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
2
Higher saturated fat intake associated with increased mortality in nonmetastatic prostate cancer
3
NeoBLAST trial tests active surveillance after complete response in MIBC
4
What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed
5